Jilin Aodong Pharmaceutical Group Co., Ltd. specializes in the manufacturing and marketing of pharmaceutical products. Besides, the group offers food products. Net sales break down by activity as follows: - sale of pharmaceutical products (89.4%); - sale of food products (6.8%); - other (3.8%). All sales are in China.

Employees

5,050

Sector

Pharmaceuticals

Calendar

10-23 Ex-dividend date - 0.2 CNY

More about the company

Quotes

Date	Price	Change	Volume
19/10/26	CN¥17.23	+0.76%	7,371,352
16/10/26	CN¥17.10	-0.29%	10,803,725
15/10/26	CN¥17.15	-1.72%	9,681,540
14/10/26	CN¥17.45	+0.29%	7,615,715
13/10/26	CN¥17.40	-0.57%	6,842,057

End-of-day quote Shenzhen S.E.

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Jilin Aodong Pharmaceutical Group Co., Ltd.

Company calendar

End-of-day quote Shenzhen S.E. 19/10/2026			5-day change	1st Jan Change
17.23 ^CNY	+0.76%		-1.54%	-11.78%

10-15	Jilin Aodong Pharmaceutical Group Co., Ltd. Announces Interim Profit Distribution Plan for 2026 to Be Implemented (A Shares), payable on October 23, 2026	CI
08-31	Jilin Aodong Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for the First Half of 2026	CI

Market Cap	20.2B 3.02B 2.69B 2.49B 2.27B 4.26B 286B 4.33B 29.92B 11.76B 150B 11.33B 11.1B 478B	P/E 2024	13.1x	P/E 2025	9.57x
Enterprise Value	19.48B 2.91B 2.6B 2.4B 2.19B 4.1B 276B 4.17B 28.84B 11.34B 144B 10.93B 10.7B 461B	EV / Sales 2024	7.76x	EV / Sales 2025	9.49x
Free-Float	66.63%	Yield 2024	2.9%	Yield 2025	2.56%

10-15	Jilin Aodong Pharmaceutical Group Co., Ltd. Announces Interim Profit Distribution Plan for 2026 to Be Implemented (A Shares), payable on October 23, 2026	CI
08-31	Jilin Aodong Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for the First Half of 2026	CI
08-28	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-09	China Approves Aodong Subsidiary's Levocarnitine Injection	MT
05-21	Jilin Aodong Pharmaceutical Gets China Approval for Supplemental Registration of Heart Drug	MT
05-12	Jilin Aodong Pharmaceutical Group Co., Ltd. Approves Final Cash Dividend on A Shares for the Year 2025, Payable on 08 July 2026	CI
04-29	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-20	Jilin Aodong Pharmaceutical's Attributable Profit Jumps 54% in 2025	MT
04-18	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-13	Aodong Pharmaceutical's Subsidiary Gets Nod to Market 10 Traditional Chinese Medicines	MT
01-27	Beijing Sun-Novo Pharmaceutical Research Co., Ltd. cancelled the acquisition of Jiangsu Langyan Life Technology Holdings Co., Ltd. from Li Qian, Ganzhou Langyi Investment Center (Limited Partnership) and Other shareholders.	CI
30/10/25	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
21/10/25	Aodong Pharmaceutical Gets China Supplementary Nod for Anti-Opioid Medication	MT

1 day	+0.76%
1 week	-1.54%
Current month	-1.03%
1 month	-1.88%
3 months	-4.60%
6 months	-5.38%
Current year	-11.78%

Jilin Aodong Pharmaceutical Group Co., Ltd. Stock

Stocks

000623

CNE000000719

Pharmaceuticals

Valuation: Jilin Aodong Pharmaceutical Group Co., Ltd.

Chart: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest news: Jilin Aodong Pharmaceutical Group Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	17	17.56
1 month	17	17.91
Current year	16.36	20.93
1 year	16.36	22.08
3 years	12.49	22.08
5 years	12.49	22.08
10 years	12.49	29.43

Manager	Title	Age	Since
Shu Qin Guo CEO	Chief Executive Officer	63	17/07/2017
Kai Yang DFI	Director of Finance/CFO	49	01/05/2004
Shu Yuan Zhang DFI	Director of Finance/CFO	54	18/06/2007

Director	Title	Age	Since
Shu Qin Guo BRD	Director/Board Member	63	01/02/2000
Shu Yuan Zhang BRD	Director/Board Member	54	17/07/2020
Xiu Lin Li CHM	Chairman	74	18/05/2005

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/25/25 A	An Ning Li	Buy		100	0.0000%
7/29/24 A	Xiu Lin Li	Buy	Chairman	350,000	0.0302%
7/29/24 A	Shu Qin Guo	Buy	Chief Executive Officer	320,000	0.0276%

	2024	2025
Net sales	2.61B 390M 348M 322M 293M 550M 37.01B 559M 3.87B 1.52B 19.34B 1.46B 1.43B 61.84B	2.34B 349M 311M 288M 262M 492M 33.11B 500M 3.46B 1.36B 17.3B 1.31B 1.28B 55.31B
Net income	1.55B 232M 207M 192M 174M 327M 21.99B 332M 2.3B 903M 11.5B 870M 852M 36.75B	2.4B 358M 319M 296M 269M 505M 33.96B 513M 3.55B 1.39B 17.75B 1.34B 1.32B 56.74B
Net Debt	-386M -57.72M -51.45M -47.66M -43.33M -81.31M -5.47B -82.65M -572M -225M -2.86B -217M -212M -9.14B	-724M -108M -96.51M -89.4M -81.28M -153M -10.26B -155M -1.07B -422M -5.36B -406M -398M -17.15B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JILIN AODONG PHARMACEUTICAL GROUP CO., LTD.	+0.76%	-1.54%	-14.83%	+6.49%	3B
ELI LILLY AND COMPANY	-1.33%	+4.88%	+54.50%	+109.94%	1,120B
JOHNSON & JOHNSON	-0.69%	-3.77%	+31.35%	+66.62%	616B
ABBVIE INC.	-0.96%	+0.55%	+23.13%	+94.26%	504B
ROCHE HOLDING AG	+0.24%	+5.58%	+33.98%	+59.40%	367B
MERCK & CO., INC.	-1.59%	-1.25%	+69.39%	+43.02%	360B
NOVARTIS AG	-0.40%	+3.53%	+19.17%	+46.55%	288B
ASTRAZENECA PLC	-0.37%	+3.11%	-1.26%	+18.23%	258B
AMGEN INC.	-1.75%	+1.76%	+42.21%	+51.44%	234B
GILEAD SCIENCES, INC.	-2.00%	+1.75%	+24.64%	+95.14%	194B
Average	-0.81%	+1.97%	+28.23%	+59.11%	394.39B
Weighted average by Cap.	-0.99%	+2.42%	+37.86%	+75.47%